Document is current

Article History

Received: 30 April 2021

Accepted: 26 July 2021

First Online: 7 August 2021

Declarations

:

: SF has received personal fees from Astellas Pharma, Celgene, Chugai Pharmaceutical, Eisai, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis, Ortho Clinical Diagnostics, Otsuka, and Pfizer, all outside the submitted work. SC has received financial support from Astellas Pharma, Ono Pharmaceutical Co, Kyowa-Kirin, Takeda Pharmaceuticals, Sanofi, Bristol-Myers Squibb, and Chugai Pharmaceutical. M Kizaki has received personal fees from Bristol-Myers Squibb, Celgene, Novartis Pharma, Janssen Pharma, and Sumitomo Dainippon Pharma, all outside the submitted work. M Kizaki also received grants and personal fees from Takeda, Kyowa Kirin, and Ono Pharmaceutical, as well as grants from Chugai Pharmaceutical and Daiichi-Sankyo, all outside the submitted work. TN has received personal fees from Eisai, Astellas Pharma, Nippon Shinyaku, Bristol-Myers Squibb, and Sysmex, all outside the submitted work. Y Maeda has received honoraria from Mundipharma, Kyowa-Kirin, Bristol-Myers Squibb, Chugai Pharma, Pfizer, Celgene, Novartis, and Pfizer. Y Maeda also received research funding from Astellas Pharma, Bristol-Myers Squibb, Takeda, Kyowa Kirin, and Chugai Pharmaceutical. TS has received grants from Astellas Pharma during the conduct of the study. TS also received personal fees from Eisai, Novartis, Kyowa Kirin, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, Ono Pharmaceutical, Pfizer, Janssen Pharmaceutical, and Otsuka Pharmaceutical, all outside the submitted work. KU has received grants and personal fees from Astellas Pharma, Alexion Pharmaceuticals, AbbVie, Gilead, SymBio Pharmaceuticals, Daiichi Sankyo, Otsuka Pharmaceutical, Novartis, Bristol-Myers Squibb, Ono Pharmaceutical, Celgene, Takeda Pharmaceutical, Nippon, Boehringer Ingelheim, and Kyowa Kirin. KU also received grants from Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Janssen Pharmaceutical, Mundipharma, Astellas-Amgen-Biopharma, Apellis Pharmaceuticals, Nippon Shinyaku, and Pfizer. KU also received personal fees from Eisai, MSD, SymBio Pharmaceuticals, PharmaEssentia Corp., and Yakult Honsha, all outside the submitted work. YK received grants, personal fees, and other support from Pfizer; YK also received personal fees from Astellas and Symbio, all outside the submitted work. JK has received other support from Astellas during the conduct of the study; JK has also received grants and personal fees from Astellas outside the submitted work. M Kusano, QL, EB, and N Hasabou are all employees of Astellas Pharma. N Hosono, HY, NA, KA, KK, TH, MH, MN, TI, MO, and Y Morita have no financial relationships to disclose.